Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Corre

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Targeted Oncology|June 13, 2023
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 StudyHélène Babey, Philippe Jamme, Hubert Curcio, et al.
Journal of Thoracic Disease|December 23, 2017
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC GroupHervé Le Caer, Isabelle Borget, Romain Corre, et al.
Journal of Geriatric Oncology|May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 studySébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
The Lancet. Respiratory Medicine|November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 studyHervé Léna, Laurent Greillier, Claire Cropet, et al.
Cancer Medicine|February 6, 2020
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH studyKarim Amrane, Margaux Geier, Romain Corre, et al.
The Lancet Regional Health. Europe|September 15, 2022
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studiesDidier Debieuvre, Olivier Molinier, Lionel Falchero, et al.
Cancers|February 15, 2022
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)Laurent Greillier, Manon Gauvrit, Elena Paillaud, et al.
Targeted Oncology|November 15, 2023
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2014
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordancesFlorian Cabillic, Audrey Gros, Frédéric Dugay, et al.
Mabs|March 10, 2015
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasiaNicolas Azzopardi, Sophie Dupuis-Girod, David Ternant, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Targeted Oncology|June 13, 2023
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 StudyHélène Babey, Philippe Jamme, Hubert Curcio, et al.
Journal of Thoracic Disease|December 23, 2017
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC GroupHervé Le Caer, Isabelle Borget, Romain Corre, et al.
Journal of Geriatric Oncology|May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 studySébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
The Lancet. Respiratory Medicine|November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 studyHervé Léna, Laurent Greillier, Claire Cropet, et al.
Cancer Medicine|February 6, 2020
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH studyKarim Amrane, Margaux Geier, Romain Corre, et al.
The Lancet Regional Health. Europe|September 15, 2022
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studiesDidier Debieuvre, Olivier Molinier, Lionel Falchero, et al.
Cancers|February 15, 2022
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)Laurent Greillier, Manon Gauvrit, Elena Paillaud, et al.
Targeted Oncology|November 15, 2023
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)Estelle Dhamelincourt, Renaud Descourt, Gaelle Rousseau-Bussac, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2014
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordancesFlorian Cabillic, Audrey Gros, Frédéric Dugay, et al.
Mabs|March 10, 2015
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasiaNicolas Azzopardi, Sophie Dupuis-Girod, David Ternant, et al.
Pageof 6